- FDA Regulatory + Risk Management Counseling
- False Claims Act + Other Whistleblower Actions
- Fraud + Abuse Litigation + Investigations
- Health Care + Life Sciences
- Litigation + Trial
- Pharmaceutical + Medical Device Litigation + Counseling
- Product Liability
- State Attorneys General
- White Collar Litigation + Investigations
- Past member, Board of Directors, Public Interest Law Center
Education
- Villanova University Charles Widger School of Law, J.D., cum laude, 2003, member, Villanova Moot Court Executive Board
- Kenyon College, B.A., 1997, English and economics
Bar Admissions
- New Jersey
- Pennsylvania
Court Admissions
- U.S. Court of Appeals, Second Circuit
- U.S. Court of Appeals, Third Circuit
- U.S. District Court, Eastern District of Pennsylvania
- Speaker, “Ethical Oversight and Best Practices: AI Integration in Compliance Departments,” ACC Greater Philadelphia’s Ethics & Compliance CLE Webinar, March 19, 2025.
- Speaker, “Breaking Boundaries – A Conversation with Kelly Mi Li from Bling Empire,” Troutman Pepper, June 8, 2021.
- Co-author, “A Model’s Credibility Is in the Details: FDA Draft Guidance on the Use of AI Models in Drug and Biological Product Development,” Troutman Pepper Locke, February 12, 2025.
- Co-author, “FDA Finalizes Guidance on Communications Regarding Unapproved Uses of Medical Products,” Troutman Pepper Locke, January 22, 2025.
- Co-author, “FDA Issues New Draft Guidance for Unapproved Use Communications,” Troutman Pepper, October 25, 2023.
- Mentioned, “Acella’s $46.5M Drug Recall Settlement Gets Initial Signoff,” Law360, February 7, 2024.